Redefining Medicine for a Healthier Tomorrow.
Our mission is to revolutionise the way the world approaches healthcare. Our focus is on investigational & psychotropic medicines, healthcare technology, and novel consumer health products.
Starting Materials & APIs
We work with certified cultivators and manufacturers around the world to deliver only the best APIs and starting materials
Wholesale Distribution
With operations in Australia, UK, Europe, Switzerland, Japan, Malaysia, and USA we serve clients across 5 continents
Manufacturing
Our ISO-accredited clean rooms and GMP standards in Australia, Czechia, Japan, and UK mean our wellness solutions and medicines are guaranteed to meet quality standards.
Brand Equity & IP
Over 15 years BXN has built globally recognized brands, trusted by businesses and consumers. These include: Bioxyne, PCC®, Dr. Watson®, Breathe Life Sciences, Apothecary® and more
Who we are
Bioxyne is an Australian life sciences, pharmaceutical and consumer health products company. Our consumer health products have been developed and sold globally for more than 15 years.
Bioxyne is committed to bringing science to wellbeing – everything we do is underpinned by a strong clinical and scientific foundation. From plant based foods, to novel foods and consumer health products, to investigational and new age medicines.
Bioxyne is the parent company of Breathe Life Sciences, licensed by the Australian government to import, export, manufacture and wholesale Schedule 3,4 and 8 medicines.
BLS operates in Australia, Japan, UK, Europe manufacturing for and supplying the pharmaceutical industry with APIs and starting materials for investigational medicines, and the consumer health products and wellness industry B2B and B2C.
Our Products
Explore our science and wellbeing hub
Bioxyne is an Australian life sciences and health products company. Our consumer health products have been developed and sold globally for more than 15 years.
Breathe Life Sciences (BLS Wholesalers PTY Ltd) is a leading Sponsor of medicinal cannabis in Australia supplying cultivators, manufacturers, pharmacies and patients nation wide. The Breathe Life Sciences Group was acquired by Bioxyne in May 2023 and is a 100% wholly owned subsidiary.
What we stand for
We believe that investigational and psychotropic medicines could lead to safer and more efficacious treatment of various diseases.
We are researching and developing psilocybin in the hope to discover a safer and more efficacious treatment for depression, and various mental health conditions.
Our mission is to expedite the adoption and acceptance of these new compounds, particularly in those who current treatments have failed, and to successfully gain marketing approval for the medicines we manufacture.
As a licensed pharmaceutical sponsor in Australia Breathe Life Sciences operates in a highly regulated environment. Under our ODC and QLD Health licenses we import, warehouse, and supply bulk GACP starting materials to manufacturers and pharmacy, and GMP manufactured finished products to patients via special access pathways, following rigorous SOPs, controlling chain of custody and maintaining compliance with the use of secure pharmacy and inventory tracking technology.
Research & Development of Novel Treatments for Depression & Affective Disorders
In February 2024 BLS was granted Australia’s first GMP manufacturing license for MDMA and Psilocybin opening significant opportunities to research, develop and commercialise novel medicines targeting mental health disorders in Australia and globally.
BLS Wholesalers is our wholly owned subsidiary, licensed by TGA and ODC for import, export, warehouse, and wholesale of Schedules 3, 4, 8 medicines, with pending GMP certification and Schedule 9 license.
Dr Watson® achieves FSA listing, and approval for exclusive Amazon Vendor pilot for CBD in UK, EU, Japan
In the UK and EU, Dr Watson CBD products are classed as Novel Foods by the FSA. Breathe Life Sciences and Dr Watson are one of only a dozen approved Amazon vendors for CBD products in the UK and EU (not available in Australia).
Machine Learning Powered B2B Wholesale and Custody Technology
Through an exclusive business arrangement, Breathe Life Sciences is working with Europes leading B2B cannabis technology platform, CanXChange, to build greater market access for sponsors and manufacturers of medical cannabis, and pharmacies in Australia.
CanXChange Australia, powered by BLS Wholesalers Pty
RECENT POSTS
Our News
Have any Questions?
If you have any questions, please feel free to drop us a message or call use now!
What we stand for
We believe in redefining medicine, from the food we eat, to the supplements we take, to the medications we are prescribed.
We believe that novel psychedelic compounds may prove a safer and more efficacious treatment for various mental health conditions.
Our mission is to expedite the adoption and acceptance of these new compounds, particularly in those who current treatments have failed, and to successfully gain marketing approval for the medicines we manufacture.
As a licensed pharmaceutical sponsor in Australia Breathe Life Sciences operates in a highly regulated environment. Under our ODC and QLD Health licenses (BLS Wholesalers Pty Ltd) we import, warehouse, and supply bulk GACP starting materials to manufacturers and pharmacy, and GMP manufactured finished products to patients via special access pathways, following rigorous SOPs, controlling chain of custody and maintaining compliance with the use of secure pharmacy and inventory tracking technology.
We Work With
